At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Budesonide plus Prevacid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Budesonide plus Prevacid and placebo plus Prevacid for Eosinophilic Esophagitis. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This study is designed to evaluate whether or not oral viscous budesonide is effective in treating children with Eosinophilic Esophagitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesUnited States
CollaboratorsMeritage Pharma, Inc.
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedMar 2008
Primary CompletionSep 2009
TodayJul 2026
First PostedMar 19, 2008
Enrollment StartFeb 1, 2008
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.3 years ago
Interventions
Budesonide plus Prevaciddrug
Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
placebo plus Prevaciddrug
Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.